Abstract
Background and aims The rectosigmoid brake, characterized by retrograde cyclic motor patterns on high-resolution colonic manometry has been postulated as a contributor to the maintenance of bowel continence. Sacral neuromodulation (SNM) is an effective therapy for faecal incontinence, but its mechanism of action is unclear. This study aims to investigate the colonic motility patterns in the distal colon of patients with faecal incontinence, and how these are modulated by SNM.
Methods A high-resolution fibre-optic colonic manometry catheter, containing 36 sensors spaced at 1-cm intervals, was positioned in patients with faecal incontinence undergoing Stage 1 SNM. One hour of pre-meal and post-meal recordings were obtained followed by pre- and post-meal recordings with suprasensory SNM. A 700-kcal meal was given. Data were analysed to identify propagating contractions.
Results Fifteen patients with faecal incontinence were analysed. Patients had an abnormal meal response (fewer retrograde propagating contractions compared to controls; p=0.027) and failed to show a postmeal increase in propagating contractions (mean 17 ± 6/h pre-meal vs 22 ± 9/h post-meal, p = 0.438). Compared to baseline, SNM significantly increased the number of retrograde propagating contractions in the distal colon (8 ± 3/h pre-meal vs 14 ± 3/h pre-meal with SNM, p = 0.028). Consuming a meal did not further increase the number of propagating contractions beyond the baseline upregulating effect of SNM.
Conclusion The rectosigmoid brake was suppressed in this cohort of patients with faecal incontinence. SNM may exert a therapeutic effect by modulating this rectosigmoid brake.
Background and context The rectosigmoid brake, characterized by retrograde propagating motility patterns, has been postulated to contribute to the maintenance of continence. The mechanisms of action of sacral neuromodulation remain inadequately understood and may include modulation of the rectosigmoid brake.
New findings We found that patients with faecal incontinence had an impaired rectosigmoid brake, characterized by a reduced frequency of colonic motor patterns in response to a meal. Rectosigmoid brake activity was upregulated by sacral neuromodulation.
Limitations This was a small cohort of patients with heterogenous faecal incontinence subtypes.
Impact Attenuation of the rectosigmoid brake is a biomarker of faecal incontinence. Rectosigmoid brake responses offer a therapeutic target to evaluate and refine sacral neuromodulation protocols.
Lay summary Patients with faecal incontinence had an attenuated rectosigmoid brake, characterised by fewer postprandial retrograde propagating contractions in the distal colon, however, the rectosigmoid brake function was improved by sacral neuromodulation.
Competing Interest Statement
Conflicts of Interest: GOG is a shareholder and Director of Alimetry and The Insides Company and holds intellectual property in the field of gastrointestinal electrophysiology and therapeutics. IB is a shareholder in the Insides Company. NP and PD hold intellectual property in the field of gastric electrophysiology and is a shareholder in FlexiMap Ltd. No commercial financial support was received for this study. All remaining authors (AL, CV, NP, SS, PD) have no conflicts of interest to declare.
Funding Statement
Financial Support: John Mitchell Crouch Fellowship, Royal Australasian College of Surgeons; Health Research Council of New Zealand.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the New Zealand Health and Disability Ethics Committee (ref: 15/NTA/175). All participants provided informed written consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest: GOG is a shareholder and Director of Alimetry and The Insides Company and holds intellectual property in the field of gastrointestinal electrophysiology and therapeutics. IB is a shareholder in the Insides Company. NP and PD hold intellectual property in the field of gastric electrophysiology and is a shareholder in FlexiMap Ltd. No commercial financial support was received for this study. All remaining authors (AL, CV, NP, SS, PD) have no conflicts of interest to declare.
Financial Support: John Mitchell Crouch Fellowship, Royal Australasian College of Surgeons; Health Research Council of New Zealand.
Data availability statement: The datasets generated during and/or analysed during the current study are not publicly available. Data sharing requests will be considered at the corresponding authors discretion.
Updated figures.
Data Availability
Data availability statement: The datasets generated during and/or analysed during the current study are not publicly available. Data sharing requests will be considered at the corresponding authors discretion.
